Pharmacological Treatment of Child and Adolescent Disruptive Behaviour Disorders: Between the Scylla and Charybdis,What Do the Data Say?

Pringsheim T Hirsch L Gardner DM , The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 1: Psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42–51.

Pringsheim T Hirsch L Gardner DM , The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers. Can J Psychiatry. 2015;60(2):52–61.

Gorman DA Gardner DM Murphy AL , Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60(2):62–76.

World Health Organization (WHO). Mental health: New understanding, new hope [report]. Geneva (CH): WHO; 2001.

Pringsheim T Lam D Patten SB . The pharmacoepidemiology of antipsychotics in Canadian children and adolescents: 2005 to 2009. J Child Adolesc Psychopharmacol. 2011;21(6):537–543.

Pringsheim T Lam D Ching H , Metabolic and neurological complications of second generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651–668.

Brault MC Lacourse É. Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994–2007. Can J Psychiatry. 2012;57(2):93–101.

Scotto Rosato N Correll CU Pappadopulos E , Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics. 2012;129(6):e1577–e1586.

Read J Fosse R Moskowitz A , The traumagenic neurodevelopmental model of psychosis revisited. Neuropsychiatry. 2014;4(1):65–79.

Neuhut R Lindenmayer JP Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication. J Child Adolesc Psychopharmacol. 2009;19(4):415–422.